Literature DB >> 18842320

The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.

Ya-Hui Tsai1, Wan-Fen Kuang, Tsai-Yi Lu, Jia-Horng Kao, Ming-Yang Lai, Chun-Jen Liu, Pei-Jer Chen, Lih-Hwa Hwang.   

Abstract

BACKGROUND/AIMS: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 usually respond better to interferon (IFN) treatment than those infected with genotype 1. In this study, we investigated whether the non-structural 5A protein (NS5A) of HCV genotypes 1 and 2 (1b-NS5A and 2a-NS5A, respectively) exerted differential counteractivities against IFN treatment.
METHODS: We compared the inhibitory effects of 1b-NS5As and 2a-NS5As on IFN activity. We also investigated the replication inhibition of HCV subgenomic replicons containing 1b-NS5A or 2a-NS5A in response to IFN treatment.
RESULTS: 1b-NS5As exerted more profound inhibitory effects on IFN activity than 2a-NS5As. The replication of the 2a-NS5A-containing replicons was more sensitive to IFN treatment than that of the 1b-NS5A-containing replicons. Deletion of the interferon sensitivity-determining region/protein kinase R-binding domain (PKR-BD), the V3 domain, or the C-terminus region of NS5A significantly abrogated its anti-IFN activity. Domain swapping between 1b-NS5A and 2a-NS5A in the V3 domain and/or the C-terminus region resulted in a transfer of their anti-IFN activity.
CONCLUSIONS: 1b-NS5As exert higher magnitudes of IFN antagonism than do 2a-NS5As. The V3 and the C-terminus regions are responsible for the differential anti-IFN effects. This phenomenon may partly explain the genotype-linked differences in the response of HCV to IFN treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842320     DOI: 10.1016/j.jhep.2008.06.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

1.  Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Authors:  Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Ke Ih Kim; Yoshi-hiro Ide; Lin Deng; Ikuo Shoji; Yasuhito Tanaka; Yutaka Hasegawa; Mitsuhiro Ota; Hak Hotta
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

2.  Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Nikolaus Jilg; Lei Zhao; Dahlene N Fusco; Hong Zhao; Kaku Goto; Du Cheng; Esperance A Schaefer; Leiliang Zhang; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Lee F Peng; Niwat Maneekarn; Raymond T Chung; Wenyu Lin
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

3.  Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR.

Authors:  Govindarajan Sudha; Subburaj Yamunadevi; Nidhi Tyagi; Saumitra Das; Narayanaswamy Srinivasan
Journal:  BMC Struct Biol       Date:  2012-11-13

4.  Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.

Authors:  Ahmed El-Shamy; Ikuo Shoji; Soo-Ryang Kim; Yoshihiro Ide; Susumu Imoto; Lin Deng; Seitetsu Yoon; Takashi Fujisawa; Satoshi Tani; Yoshihiko Yano; Yasushi Seo; Takeshi Azuma; Hak Hotta
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

5.  New insights regarding HCV-NS5A structure/function and indication of genotypic differences.

Authors:  Lilian Ht Yamasaki; Helen A Arcuri; Ana Carolina G Jardim; Cintia Bittar; Isabel Maria Vg de Carvalho-Mello; Paula Rahal
Journal:  Virol J       Date:  2012-01-12       Impact factor: 4.099

6.  Dengue virus targets the adaptor protein MITA to subvert host innate immunity.

Authors:  Chia-Yi Yu; Tsung-Hsien Chang; Jian-Jong Liang; Ruei-Lin Chiang; Yi-Ling Lee; Ching-Len Liao; Yi-Ling Lin
Journal:  PLoS Pathog       Date:  2012-06-28       Impact factor: 6.823

7.  Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling.

Authors:  Ryuichi Sugiyama; Asako Murayama; Sayuri Nitta; Norie Yamada; Megumi Tasaka-Fujita; Takahiro Masaki; Hussein Hassan Aly; Masaaki Shiina; Akihide Ryo; Koji Ishii; Takaji Wakita; Takanobu Kato
Journal:  Oncotarget       Date:  2017-12-21

8.  Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.

Authors:  H J Yuan; M Jain; K K Snow; M Gale; W M Lee
Journal:  J Viral Hepat       Date:  2009-07-28       Impact factor: 3.728

9.  Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication.

Authors:  Yin-Ju Chen; Yu-Hsuan Chen; Lu-Ping Chow; Ya-Hui Tsai; Pei-Hong Chen; Chi-Ying F Huang; Wei-Tzu Chen; Lih-Hwa Hwang
Journal:  J Biol Chem       Date:  2010-07-02       Impact factor: 5.157

Review 10.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.